Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Prostate Cancer

  Free Subscription

Articles published in Prog Urol

Retrieve available abstracts of 44 articles:
HTML format

Single Articles

    October 2023
  1. DARIANE C, Chierigo F, Ouellet V, Delvoye N, et al
    Analysis of active surveillance uptake for localized prostate cancer in Quebec in 2016: A Canadian bicentric study and comparison with 2010 data.
    Prog Urol. 2023 Oct 17:S1166-7087(23)00234-8. doi: 10.1016/j.purol.2023.
    PubMed     Abstract available

  2. DANG VT, Pericart S, Manceau C, Aziza R, et al
    Significant prostate cancer risk after MRI-guided biopsy showing benign findings: Results from a cohort of 381 men.
    Prog Urol. 2023 Oct 17:S1166-7087(23)00237-3. doi: 10.1016/j.purol.2023.
    PubMed     Abstract available

  3. PEYROTTES A, Roupret M, Fiard G, Fromont G, et al
    [Early detection of prostate cancer: Towards a new paradigm?].
    Prog Urol. 2023 Oct 5:S1166-7087(23)00219-1. doi: 10.1016/j.purol.2023.
    PubMed     Abstract available

    September 2023
  4. BANDELIER Q, Bastide C, Charvet AL, Leclercq L, et al
    Active surveillance in favorable intermediate-risk prostate cancer: A single-center experience.
    Prog Urol. 2023 Sep 30:S1166-7087(23)00227-0. doi: 10.1016/j.purol.2023.
    PubMed     Abstract available

  5. DEBARD C, Margue G, Klein C, Rompre-Brodeur A, et al
    [Oncological and functional results of focal treatment of localized prostate cancer with HIFU].
    Prog Urol. 2023 Sep 26:S1166-7087(23)00215-4. doi: 10.1016/j.purol.2023.
    PubMed     Abstract available

    May 2023
  6. BERCHICHE W, Long Depaquit T, Baboudjian M, Barret E, et al
    Mid-term oncologic outcomes of radical prostatectomy in lymph node metastatic prostate cancer patients.
    Prog Urol. 2023 May 27:S1166-7087(23)00090-8. doi: 10.1016/j.purol.2023.
    PubMed     Abstract available

    April 2023
  7. CECCHI M, Ninot G, Rebillard X, Thuret R, et al
    [Which non pharmacological interventions should be offered to patients treated with androgen deprivation therapy for prostate cancer? A systematic review].
    Prog Urol. 2023 Apr 28:S1166-7087(23)00085-4. doi: 10.1016/j.purol.2023.
    PubMed     Abstract available

  8. BLEZIEN O, Bentellis I, Tibi B, Shaikh A, et al
    Robot assisted radical prostatectomy in fit older patients compared to a standard population: Clinical characteristics, surgical, oncological and functional outcomes.
    Prog Urol. 2023;33:272-278.
    PubMed     Abstract available

    February 2023
  9. PAYRARD-STARCK C, Fourcade A, An Nguyen T, Tissot V, et al
    Direct comparison between Grade Group assessed on systematic and MRI/ultrasound fusion targeted biopsies correlated to the radical prostatectomy specimens in patients with prostate cancer.
    Prog Urol. 2023 Feb 3:S1166-7087(23)00025-8. doi: 10.1016/j.purol.2023.
    PubMed     Abstract available

    December 2022
  10. MAROLLEAU J, Nguyen TA, Doucet L, Coste A, et al
    [Morbidity of extended pelvic lymphadenectomy during robot-assisted laparoscopic prostatectomy for localized cancer prostate].
    Prog Urol. 2022;32:1455-1461.
    PubMed     Abstract available

  11. MANDOORAH Q, Benamran D, Pinar U, Seisen T, et al
    Biochemical relapse predictive factors in patients with lymph node metastases during radical prostatectomy.
    Prog Urol. 2022;32:1462-1468.
    PubMed     Abstract available

    November 2022
  12. TRETARRE B, Trouche-Sabatier SG, Foucan AS, Abdo N, et al
    [Adhesion of urologists to the recommendations of the French Urological Association Cancer Committee (CCAFU) in the imaging work-up of localized prostate cancer].
    Prog Urol. 2022 Nov 4. pii: S1166-7087(22)00426.
    PubMed     Abstract available

  13. CORBEL A, Leroy V, Vesval Q, Rebillard A, et al
    [Connected APA tools and prostate cancer: Literature review and experience feedback].
    Prog Urol. 2022;32:880-887.
    PubMed     Abstract available

  14. PLOUSSARD G, Roubaud G, Barret E, Beauval JB, et al
    French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance.
    Prog Urol. 2022;32:1373-1419.
    PubMed     Abstract available

  15. PLOUSSARD G, Fiard G, Barret E, Brureau L, et al
    French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease.
    Prog Urol. 2022;32:1275-1372.
    PubMed     Abstract available

  16. MATHIEU R, Doizi S, Bensalah K, Lebacle C, et al
    [Complications in urological surgery: Prostate surgery].
    Prog Urol. 2022;32:953-965.
    PubMed     Abstract available

    October 2022
  17. MRAD DALI K, Rahoui M, Chaker K, Ouanes Y, et al
    Positive urine culture prior to transrectal prostate biopsy was not associated with infectious complications development.
    Prog Urol. 2022;32:830-835.
    PubMed     Abstract available

    September 2022
  18. MANOLACHE NG, Mjaess G, Diamand R, Albisinni S, et al
    [Prostate cancer, androgen deprivation, and risk of COVID-19 infection : A systematic review and meta-analysis].
    Prog Urol. 2022 Sep 13. pii: S1166-7087(22)00396.
    PubMed     Abstract available

    August 2022
  19. AZOULAI D, Boustany J, Peyromaure M, Abou Chakra M, et al
    The proportion of potential candidates for focal therapy in localized prostate cancer in a real-life cohort and their final pathologic results.
    Prog Urol. 2022 Aug 5. pii: S1166-7087(22)00338.
    PubMed     Abstract available

    July 2022
  20. BAJEOT AS, Roumiguie M, Rebillard X, Descotes JL, et al
    [De novo or secondary metastatic prostate cancer management in France: Observational study from "sentinel multidisciplinary meeting" of the French Association of Urology].
    Prog Urol. 2022 Jul 1. pii: S1166-7087(22)00127.
    PubMed     Abstract available

    June 2022
  21. MIRO-PADOVANI M, Batista da Costa J, Salomon L, Ingels A, et al
    [High risk localized and locally advanced prostate cancer: Long-term oncological outcomes after prostatectomy].
    Prog Urol. 2022 Jun 27. pii: S1166-7087(22)00128.
    PubMed     Abstract available

  22. BABOUDJIAN M, Gauthe M, Barret E, Brureau L, et al
    How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du Cancer de la Prostate Non Metastatique Resistant a la Castration ?
    Prog Urol. 2022;32.
    PubMed     Abstract available

  23. LASSERRE M, Sargos P, Barret E, Beauval JB, et al
    Narrative review of PET/CT performances at biochemical recurrence in prostate cancer after radical prostatectomy and impact on patient disease management: Revue narrative a propos des performances de la TEP/TDM en cas de recidive biochimique apres pro
    Prog Urol. 2022;32.
    PubMed     Abstract available

  24. DIAMAND R, Mjaess G, Ploussard G, Fiard G, et al
    Magnetic Resonance Imaging-Targeted Biopsy and Pretherapeutic Prostate Cancer Risk Assessment: a Systematic Review: Biopsie ciblee par Imagerie par resonance magnetique et evaluation pre-therapeutique du risque de cancer de la prostate : revue systema
    Prog Urol. 2022;32.
    PubMed     Abstract available

  25. MARTEL P, Rakauskas A, Dagher J, La Rosa S, et al
    The benefit of adopting Microultrasound in the prostate cancer imaging pathway: A lesion-by-lesion analysis: Biopsies prostatiques guidee par micro-echographie, quel benefice ? Une analyse lesion par lesion.
    Prog Urol. 2022;32.
    PubMed     Abstract available

  26. FIARD G, Giganti F
    How MRI is changing prostate cancer management: a focus on early detection and active surveillance: Comment l'IRM est en train de revolutionner la prise en charge du cancer de la prostate : focus sur la detection precoce et la surveillance active.
    Prog Urol. 2022;32.
    PubMed     Abstract available

  27. KLEINCLAUSS F, Ploussard G
    How imaging is changing prostate cancer management - Editorial: Comment l'imagerie peut revolutionner le traitement du cancer de la prostate - Editorial.
    Prog Urol. 2022;32.

    May 2022
  28. BABOUDJIAN M, Beauval JB, Barret E, Brureau L, et al
    [Recent advances in the management of localized high-risk prostate cancer: An update by the Prostate Cancer Committee of the French Association of Urology].
    Prog Urol. 2022 May 26. pii: S1166-7087(22)00121.
    PubMed     Abstract available

  29. GANDER J, Guandalino M, Vedrine N, Charbonnel C, et al
    [Comparison of systematic, targeted and combined prostate biopsies for the diagnosis of prostate cancer with MRI lesion].
    Prog Urol. 2022 May 13. pii: S1166-7087(22)00094.
    PubMed     Abstract available

    March 2022
  30. MARTEL P, Rakauskas A, Dagher J, La Rosa S, et al
    The benefit of adopting Microultrasound in the prostate cancer imaging pathway : A lesion-by-lesion analysis.
    Prog Urol. 2022 Mar 12. pii: S1166-7087(22)00066.
    PubMed     Abstract available

  31. SAIER E, Pinar U, De La Taille A, Irani J, et al
    [Assessment of positive surgical margins in the management of patients after radical prostatectomy for pT2 prostate cancer].
    Prog Urol. 2022 Mar 2. pii: S1166-7087(22)00030.
    PubMed     Abstract available

    February 2022
  32. LAINE-CAROFF P, Bruyere F, Mathieu R, Monleon L, et al
    The volume and thickness of preprostatic fat on MRIs are not associated with prostate cancer aggressiveness in men undergoing radical prostatectomy.
    Prog Urol. 2022 Feb 25. pii: S1166-7087(22)00029.
    PubMed     Abstract available

  33. PLOUSSARD G, Beauval JB, Mathieu R, Barret E, et al
    [DNA repair gene alterations testing in prostate cancer : A practical update by the prostate cancer committee of the french association of urology].
    Prog Urol. 2022 Feb 4. pii: S1166-7087(22)00005.
    PubMed     Abstract available

    December 2021
  34. LE BIHAN E, Derman J, Salomon L, De La Taille A, et al
    [Radical prostatectomy in patients with Gleason 6 (ISUP 1) prostate cancer: 10-year follow-up].
    Prog Urol. 2021 Dec 14. pii: S1166-7087(21)00569.
    PubMed     Abstract available

  35. PRUDHOMME T, Roumiguie M, Pericart S, Doumerc N, et al
    Assessment of oncological and functional outcomes of retropubic radical prostatectomy: An academic center experience.
    Prog Urol. 2021;31:1123-1132.
    PubMed     Abstract available

    September 2021
  36. AOUN F, Mjaess G, Abi Tayeh G, Sarkis J, et al
    Focal therapy for prostate cancer: Making the punishment fit the crime.
    Prog Urol. 2021 Sep 16. pii: S1166-7087(21)00215.
    PubMed     Abstract available

  37. DIAMANT E, de la Taille A, Lavolle A, Chahwan C, et al
    [Urethro-vesical anastomosis reconstruction using extra-peritoneal robot-assisted laparoscopy for anastomotic stenosis after radical prostatectomy].
    Prog Urol. 2021;31:591-597.
    PubMed     Abstract available

    July 2021
  38. RAVERY V, Adoumadji K, Bras Da Silva C, Vega Toro P, et al
    [MRI of the axial skeleton for evaluation of prostate cancer extent in french Guyana].
    Prog Urol. 2021 Jul 8. pii: S1166-7087(21)00164.
    PubMed     Abstract available

    June 2021
  39. DELEUZE C, Blanchet P, Gourtaud G, Senechal C, et al
    [High-intensity focused ultrasound for locally prostate cancer: An Afro-Caribbean single-center study].
    Prog Urol. 2021 Jun 18. pii: S1166-7087(21)00030.
    PubMed     Abstract available

  40. BISCANS C, Vallee M, Ingrand P, Debiais-Delpech C, et al
    Comparison between MRI and choline-PET trans-perineal target biopsies and saturation biopsies for detection and topography of intra-prostatic recurrence after primary radiation therapy for prostate cancer.
    Prog Urol. 2021 Jun 18. pii: S1166-7087(21)00116.
    PubMed     Abstract available

    April 2021
  41. TAMBWE KAYOMBO R, Leon P, Lasserre T, Fournier R, et al
    [Impact of positive surgical margins on prostate cancer prognosis].
    Prog Urol. 2021 Apr 30. pii: S1166-7087(20)30713.
    PubMed     Abstract available

  42. ROZET F, Mongiat-Artus P, Hennequin C, Beauval JB, et al
    Corrigendum to "French ccAFU guidelines-update 2020-2022: Prostate cancer" [Prog. Urol 30 (12 S) (2020), pp S136-S251].
    Prog Urol. 2021 Apr 30. pii: S1166-7087(21)00093.

  43. ROZET F, Mongiat-Artus P, Ploussard G, Roupret M, et al
    [Update on the risk of corticosterone therapy in combination with abiraterone acetate during the COVID-19 pandemic].
    Prog Urol. 2021;31:243-244.

  44. BRUYERE F, Vallee M, Legeais D, Le Goux C, et al
    [Short recommendations from the CIAFU: Interest of the urine bacterial culture performed before endo-rectal prostate biopsy].
    Prog Urol. 2021;31:245-248.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.